Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Travere Therapeutics Inc
(NQ:
TVTX
)
13.48
+0.88 (+6.98%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Sep 13, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Travere Therapeutics Inc
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
What 10 Analyst Ratings Have To Say About Travere Therapeutics
February 22, 2023
Via
Benzinga
Why CVRx Shares Are Trading Lower By 43%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
February 21, 2023
Gainers Arbe Robotics Ltd. (NASDAQ: ARBE) gained 62.8% to $7.08. Arbe Robotics is expected to report its financial results for the fourth quarter on Thursday, March 2, 2023.
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
February 21, 2023
Via
Benzinga
The Latest Analyst Ratings for Travere Therapeutics
January 30, 2023
Via
Benzinga
4 Analysts Have This to Say About Travere Therapeutics
December 05, 2022
Via
Benzinga
Where Travere Therapeutics Stands With Analysts
December 05, 2022
Via
Benzinga
Manitowoc, Helix Energy Solutions, JELD-WEN Holding And Other Big Stocks Moving Higher On Tuesday
February 21, 2023
U.S. stocks traded lower, with the Dow Jones dropping around 450 points on Tuesday. Here are some big stocks recording gains in today’s session.
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For February 21, 2023
February 21, 2023
Via
Benzinga
Travere Therapeutics Scores Accelerated FDA Approval For Rare Kidney Disease Treatment
February 21, 2023
Via
Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
February 20, 2023
Via
Benzinga
Ligand’s Partner Travere Therapeutics Announces FDA Accelerated Approval of FILSPARI™ (sparsentan), the First and Only Non-immunosuppressive Therapy for the Reduction of Proteinuria in IgA Nephropathy
February 17, 2023
From
Ligand Pharmaceuticals Incorporated
Via
Business Wire
Travere Therapeutics Announces FDA Accelerated Approval of FILSPARITM (sparsentan), the First and Only Non-immunosuppressive Therapy for the Reduction of Proteinuria in IgA Nephropathy
February 17, 2023
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
Travere Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results
February 16, 2023
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 13, 2023
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
Travere Therapeutics to Present at Upcoming Investor Conferences
February 08, 2023
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
The Nasdaq Is Rebounding: 2 Supercharged Growth Stocks to Buy in February
February 01, 2023
These two growth stocks might deliver enormous gains for shareholders this month.
Via
The Motley Fool
February PDUFA Catalysts Biotech Investors Must Know: Sanofi's Bleeding Disorder Drug, Regeneron's Twin Eylea Label Expansions, 3 Delayed Approvals And More
January 31, 2023
The year has started well for biopharma companies on the regulatory front, as most decisions handed out during January were positive. The Food and Drug Administration has already cleared four new...
Via
Benzinga
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 12, 2023
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
Travere Therapeutics Provides Corporate Update and 2023 Outlook
January 09, 2023
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
Travere Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
January 03, 2023
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 14, 2022
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For December 14, 2022
December 14, 2022
Via
Benzinga
Stocks That Hit 52-Week Lows On Monday
December 12, 2022
Monday saw 196 companies set new 52-week lows.
Via
Benzinga
Stocks That Hit 52-Week Lows On Tuesday
November 22, 2022
During Tuesday's trading, 160 companies set new 52-week lows.
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For December 5, 2022
December 05, 2022
Via
Benzinga
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
November 16, 2022
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
Travere Therapeutics, the IgA Nephropathy Foundation, and NephCure Kidney International Partner to Launch RKD & Me, a Campaign to Raise Awareness of Rare Kidney Disease
November 15, 2022
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
Travere Therapeutics to Present at Upcoming Investor Conferences
November 09, 2022
From
Travere Therapeutics, Inc.
Via
GlobeNewswire
Travere Therapeutics Earnings Perspective: Return On Capital Employed
November 03, 2022
Benzinga Pro data, Travere Therapeutics (NASDAQ:TVTX) reported Q3 sales of $53.50 million. Earnings fell to a loss of $69.66 million, resulting in a 3.91% decrease from last quarter.
Via
Benzinga
Provention Bio's Second Try, Apellis's Eye Disorder Drug Review, 3 Adcom Verdicts And More: November's Key PDUFA Catalysts Biotech Investors Must Know
November 01, 2022
October proved to be a mixed month for the Food and Drug Administration’s regulatory decisions. Two new molecular entities, or NMEs, were approved during the month, bringing the tally for the...
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit